• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

通过脂质感应核受体 PPARs、FXR 和 LXR 对 NASH 中代谢途径的转录调控。

Transcriptional Regulation of Metabolic Pathways via Lipid-Sensing Nuclear Receptors PPARs, FXR, and LXR in NASH.

机构信息

Department of Interdisciplinary Medicine, University of Bari "Aldo Moro," Bari, Italy.

Department of Basic Medical Sciences, Neurosciences and Sense Organs, University of Bari "Aldo Moro," Bari, Italy.

出版信息

Cell Mol Gastroenterol Hepatol. 2021;11(5):1519-1539. doi: 10.1016/j.jcmgh.2021.01.012. Epub 2021 Feb 2.

DOI:10.1016/j.jcmgh.2021.01.012
PMID:33545430
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8042405/
Abstract

Nonalcoholic fatty liver disease comprises a wide spectrum of liver injuries from simple steatosis to steatohepatitis and cirrhosis. Nonalcoholic steatohepatitis (NASH) is defined when liver steatosis is associated with inflammation, hepatocyte damage, and fibrosis. A genetic predisposition and environmental insults (ie, dietary habits, obesity) are putatively responsible for NASH progression. Here, we present the impact of the lipid-sensing nuclear receptors in the pathogenesis and treatment of NASH. In detail, we discuss the pros and cons of the putative transcriptional action of the fatty acid sensors (peroxisome proliferator-activated receptors), the bile acid sensor (farnesoid X receptor), and the oxysterol sensor (liver X receptors) in the pathogenesis and bona fide treatment of NASH.

摘要

非酒精性脂肪性肝病(NAFLD)是一种广泛的肝脏损伤,从单纯性脂肪变性到脂肪性肝炎和肝硬化。当肝脏脂肪变性伴有炎症、肝细胞损伤和纤维化时,即可诊断为非酒精性脂肪性肝炎(NASH)。遗传易感性和环境损伤(例如饮食习惯、肥胖)被认为是 NASH 进展的原因。在这里,我们介绍了脂质感知核受体在 NASH 的发病机制和治疗中的作用。具体来说,我们讨论了脂肪酸传感器(过氧化物酶体增殖物激活受体)、胆汁酸传感器(法尼醇 X 受体)和氧化固醇传感器(肝 X 受体)在 NASH 发病机制和真正治疗中的潜在转录作用的优缺点。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5b53/8042405/82cdc534bbaa/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5b53/8042405/9e73a3898743/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5b53/8042405/82cdc534bbaa/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5b53/8042405/9e73a3898743/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5b53/8042405/82cdc534bbaa/gr2.jpg

相似文献

1
Transcriptional Regulation of Metabolic Pathways via Lipid-Sensing Nuclear Receptors PPARs, FXR, and LXR in NASH.通过脂质感应核受体 PPARs、FXR 和 LXR 对 NASH 中代谢途径的转录调控。
Cell Mol Gastroenterol Hepatol. 2021;11(5):1519-1539. doi: 10.1016/j.jcmgh.2021.01.012. Epub 2021 Feb 2.
2
Nuclear receptors and nonalcoholic fatty liver disease.核受体与非酒精性脂肪性肝病
Biochim Biophys Acta. 2016 Sep;1859(9):1083-1099. doi: 10.1016/j.bbagrm.2016.03.002. Epub 2016 Mar 4.
3
Modulation of xenobiotic nuclear receptors in high-fat diet induced non-alcoholic fatty liver disease.高脂饮食诱导的非酒精性脂肪性肝病中外源物核受体的调控。
Toxicology. 2018 Dec 1;410:199-213. doi: 10.1016/j.tox.2018.08.007. Epub 2018 Aug 16.
4
The role of bile acids in nonalcoholic fatty liver disease and nonalcoholic steatohepatitis.胆汁酸在非酒精性脂肪性肝病和非酒精性脂肪性肝炎中的作用。
Mol Aspects Med. 2017 Aug;56:34-44. doi: 10.1016/j.mam.2017.04.004. Epub 2017 May 5.
5
Free radical biology for medicine: learning from nonalcoholic fatty liver disease.医学中的自由基生物学:从非酒精性脂肪性肝病中学习。
Free Radic Biol Med. 2013 Dec;65:952-968. doi: 10.1016/j.freeradbiomed.2013.08.174. Epub 2013 Aug 29.
6
Hepatocyte MyD88 affects bile acids, gut microbiota and metabolome contributing to regulate glucose and lipid metabolism.肝细胞髓样分化因子88影响胆汁酸、肠道微生物群和代谢组,有助于调节葡萄糖和脂质代谢。
Gut. 2017 Apr;66(4):620-632. doi: 10.1136/gutjnl-2015-310904. Epub 2016 May 5.
7
Acanthoic acid modulates lipogenesis in nonalcoholic fatty liver disease via FXR/LXRs-dependent manner.阿坎酸通过 FXR/LXRs 依赖性途径调节非酒精性脂肪性肝病中的脂肪生成。
Chem Biol Interact. 2019 Sep 25;311:108794. doi: 10.1016/j.cbi.2019.108794. Epub 2019 Aug 14.
8
Disruption of hepatic small heterodimer partner induces dissociation of steatosis and inflammation in experimental nonalcoholic steatohepatitis.肝小异二聚体伴侣的破坏可诱导实验性非酒精性脂肪性肝炎中脂肪变性和炎症的分离。
J Biol Chem. 2020 Jan 24;295(4):994-1008. doi: 10.1074/jbc.RA119.010233. Epub 2019 Dec 12.
9
The nuclear receptor FXR, but not LXR, up-regulates bile acid transporter expression in non-alcoholic fatty liver disease.核受体FXR而非LXR可上调非酒精性脂肪性肝病中胆汁酸转运蛋白的表达。
Ann Hepatol. 2015 Jul-Aug;14(4):487-93.
10
The Role of PPAR and Its Cross-Talk with CAR and LXR in Obesity and Atherosclerosis.过氧化物酶体增殖物激活受体(PPAR)及其与细胞色素 P450 家族成员 3A4(CYP3A4)和肝 X 受体(LXR)的相互作用在肥胖和动脉粥样硬化中的作用。
Int J Mol Sci. 2018 Apr 23;19(4):1260. doi: 10.3390/ijms19041260.

引用本文的文献

1
Effect of dietary polyphenols along with exercise on hepatic transcriptional regulators of lipid metabolism.膳食多酚与运动对肝脏脂质代谢转录调节因子的影响。
Front Nutr. 2025 Jul 2;12:1531327. doi: 10.3389/fnut.2025.1531327. eCollection 2025.
2
Effects of semaglutide on metabolism and gut microbiota in high-fat diet-induced obese mice.司美格鲁肽对高脂饮食诱导的肥胖小鼠代谢和肠道微生物群的影响。
Front Pharmacol. 2025 Jun 2;16:1562896. doi: 10.3389/fphar.2025.1562896. eCollection 2025.
3
Yeast hydrolysate and exercise ameliorate high-fat diet-induced obesity in C57BL/6 mice.

本文引用的文献

1
Differential effects of selective- and pan-PPAR agonists on experimental steatohepatitis and hepatic macrophages.选择性和全过氧化物酶体增殖物激活受体激动剂对实验性脂肪性肝炎和肝巨噬细胞的不同影响。
J Hepatol. 2020 Oct;73(4):757-770. doi: 10.1016/j.jhep.2020.04.025. Epub 2020 Apr 29.
2
Cilofexor, a Nonsteroidal FXR Agonist, in Patients With Noncirrhotic NASH: A Phase 2 Randomized Controlled Trial.西罗法辛,一种非甾体 FXR 激动剂,在非肝硬化 NASH 患者中的应用:一项 2 期随机对照试验。
Hepatology. 2020 Jul;72(1):58-71. doi: 10.1002/hep.31205.
3
Liver X Receptors Regulate Cholesterol Metabolism and Immunity in Hepatic Nonparenchymal Cells.
酵母水解物与运动改善高脂饮食诱导的C57BL/6小鼠肥胖。
BMC Complement Med Ther. 2025 Apr 3;25(1):126. doi: 10.1186/s12906-025-04856-4.
4
The effects and mechanisms of Xiaoyao San on nonalcoholic fatty liver disease rat based on transcriptomics and proteomics analysis.基于转录组学和蛋白质组学分析逍遥散对非酒精性脂肪性肝病大鼠的作用及机制
Sci Rep. 2025 Mar 26;15(1):10478. doi: 10.1038/s41598-025-91890-4.
5
Bile acid activated receptors: Integrating immune and metabolic regulation in non-alcoholic fatty liver disease.胆汁酸激活受体:整合非酒精性脂肪性肝病中的免疫与代谢调节
Liver Res. 2021 Sep 2;5(3):119-141. doi: 10.1016/j.livres.2021.08.003. eCollection 2021 Sep.
6
Diverting hepatic lipid fluxes with lifestyles revision and pharmacological interventions as a strategy to tackle steatotic liver disease (SLD) and hepatocellular carcinoma (HCC).通过改变生活方式和药物干预来改变肝脏脂质通量,以此作为应对脂肪性肝病(SLD)和肝细胞癌(HCC)的一种策略。
Nutr Metab (Lond). 2024 Dec 23;21(1):112. doi: 10.1186/s12986-024-00871-3.
7
Potential involvement of peroxisome proliferator-activated receptors in the inhibition of mammary lipid synthesis during diet-induced milk fat depression.过氧化物酶体增殖物激活受体在饮食诱导的乳脂肪降低过程中对乳腺脂质合成的抑制作用中的潜在参与。
J Dairy Sci. 2025 Feb;108(2):2036-2044. doi: 10.3168/jds.2024-25575. Epub 2024 Nov 8.
8
Active role of the immune system in metabolic dysfunction-associated steatotic liver disease.免疫系统在代谢功能障碍相关脂肪性肝病中的积极作用。
Gastroenterol Rep (Oxf). 2024 Oct 15;12:goae089. doi: 10.1093/gastro/goae089. eCollection 2024.
9
Emerging Therapies for Non-Alcoholic Steatohepatitis (NASH): A Comprehensive Review of Pharmacological and Non-Pharmacological Approaches.非酒精性脂肪性肝炎(NASH)的新兴疗法:药理学和非药理学方法的全面综述
Cureus. 2024 Sep 10;16(9):e69129. doi: 10.7759/cureus.69129. eCollection 2024 Sep.
10
Seabuckthorn polysaccharides mitigate hepatic steatosis by modulating the Nrf-2/HO-1 pathway and gut microbiota.沙棘多糖通过调节Nrf-2/HO-1通路和肠道微生物群减轻肝脏脂肪变性。
AMB Express. 2024 Sep 9;14(1):100. doi: 10.1186/s13568-024-01756-7.
肝 X 受体调节肝非实质细胞中的胆固醇代谢和免疫。
Int J Mol Sci. 2019 Oct 11;20(20):5045. doi: 10.3390/ijms20205045.
4
Role of Oleic Acid in the Gut-Liver Axis: From Diet to the Regulation of Its Synthesis via Stearoyl-CoA Desaturase 1 (SCD1).油酸在肠-肝轴中的作用:从饮食到通过硬脂酰辅酶 A 去饱和酶 1(SCD1)调节其合成。
Nutrients. 2019 Sep 24;11(10):2283. doi: 10.3390/nu11102283.
5
Pharmacologic Modulation of Bile Acid-FXR-FGF15/FGF19 Pathway for the Treatment of Nonalcoholic Steatohepatitis.用于治疗非酒精性脂肪性肝炎的胆汁酸-FXR-FGF15/FGF19通路的药理学调节
Handb Exp Pharmacol. 2019;256:325-357. doi: 10.1007/164_2019_228.
6
Elevated oxysterol levels in human and mouse livers reflect nonalcoholic steatohepatitis.人肝和鼠肝中氧化固醇水平升高反映非酒精性脂肪性肝炎。
J Lipid Res. 2019 Jul;60(7):1270-1283. doi: 10.1194/jlr.M093229. Epub 2019 May 21.
7
Pharmacological PPARβ/δ activation upregulates VLDLR in hepatocytes.药理学上激活过氧化物酶体增殖物激活受体β/δ可上调肝细胞中的极低密度脂蛋白受体(VLDLR)。
Clin Investig Arterioscler. 2019 May-Jun;31(3):111-118. doi: 10.1016/j.arteri.2019.01.004. Epub 2019 Apr 13.
8
Biological mechanisms and related natural modulators of liver X receptor in nonalcoholic fatty liver disease.非酒精性脂肪性肝病中肝 X 受体的生物学机制及相关天然调节剂。
Biomed Pharmacother. 2019 May;113:108778. doi: 10.1016/j.biopha.2019.108778. Epub 2019 Mar 18.
9
LXR Suppresses Inflammatory Gene Expression and Neutrophil Migration through cis-Repression and Cholesterol Efflux.LXR 通过顺式抑制和胆固醇外排抑制炎症基因表达和中性粒细胞迁移。
Cell Rep. 2018 Dec 26;25(13):3774-3785.e4. doi: 10.1016/j.celrep.2018.11.100.
10
Nuclear receptors and liver disease: Summary of the 2017 basic research symposium.核受体与肝脏疾病:2017年基础研究研讨会综述
Hepatol Commun. 2018 Jun 14;2(7):765-777. doi: 10.1002/hep4.1203. eCollection 2018 Jul.